ASH Annual Meeting and Exposition | Conference

Dr. Saunthararajah on Mechanisms of Resistance to 5-Azacytidine /Decitabine in MDS-AML

December 10th 2015

Yogenthiran Saunthararajah, MD, Department of Hematologic Oncology and Blood Disorders at Cleveland Clinic, professor of Medicine, co-leader, Developmental Therapeutics Program of the Case Comprehensive Cancer Center, discusses mechanisms of resistance to 5-azacytidine and decitabine in patients with myelodysplastic syndromes-acute myeloid leukemia.

Dr. Goy on John Theurer Cancer Center Milestone

December 9th 2015

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, director, Clinical and Translational Cancer Research, discusses an upcoming event at John Theurer Cancer Center in honor of the institution's 25th anniversary of its first bone marrow transplant.

Blinatumomab Shows High CR Rates Across Two ALL Studies

December 9th 2015

Monotherapy with blinatumomab demonstrated high complete remission or CR with partial hematological recovery rates in adult patients with Philadelphia chromosome-positive and -negative B-cell precursor acute lymphoblastic leukemia.

Response Rates Near 100% for CAR T-cell Therapies in ALL

December 8th 2015

Two CD19-targeted chimeric antigen receptor-modified T-cell therapies demonstrated complete response rates ranging from 90% to 100% in patients with high-risk acute lymphoblastic leukemia.

Dr. Kipps on Ibrutinib Versus Chlorambucil in Treatment-NaÃ¯ve CLL/SLL

December 8th 2015

Thomas J. Kipps, MD, PhD, deputy director of Research, Moores University of California, San Diego Cancer Center, professor of Medicine, University of California San Diego, School of Medicine, discusses results of the RESONATE-2 study, which compared ibrutinib versus chlorambucil in elderly patients with treatment-naÃ¯ve chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

No Safety Concerns in Trial of Ibrutinib to Early-Stage CLL

December 8th 2015

Preliminary data from an ongoing clinical trial suggest ibrutinib has an acceptable safety profile when used to prevent disease progression in patients with asymptomatic, early-stage chronic lymphocytic leukemia.

Next-Generation BTK Inhibitor Taking on Ibrutinib in CLL

December 8th 2015

Acalabrutinib has demonstrated a 95% response rate and durable remissions with a favorable safety profile in a phase I/II study for patients with chronic lymphocytic leukemia.

Dr. San Miguel on Pembrolizumab With Lenalidomide/ Dexamethasone in Multiple Myeloma

December 8th 2015

Jesus San Miguel, MD, PhD, professor of Hematology, medical director of the ClÃnica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain, discusses the Keynote-023 study, which examined pembrolizumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.

Dr. Orlowski on Bortezomib Added to Lenalidomide and Dexamethasone for Multiple Myeloma

December 7th 2015

Robert Z. Orlowski, MD, PhD, Department Chair ad interim, Department of Lymphoma/Myeloma, Division of Cancer Medicine, professor, Florence Maude Thomas Cancer Research Professorship, The University of Texas MD Anderson Cancer Center, discusses the phase III SWOG 0777 study, which examined the addition of bortezomib to lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with previously untreated multiple myeloma.

Ibrutinib Bests Temsirolimus in Relapsed/Refractory Mantle Cell Lymphoma

December 7th 2015

Ibrutinib sparks more durable remissions than temsirolimus in patients with relapsed or refractory mantle cell lymphoma.

Ibrutinib Active in Rituximab-Refractory WM

December 7th 2015

More than 80% of patients with treatment-refractory Waldenstrom's macroglobulinemia responded to single-agent therapy with ibrutinib, according to results of a preliminary clinical trial.

Pembrolizumab Combo Generates High Response Rate in Refractory Myeloma

December 7th 2015

The addition of pembrolizumab to an established multiple myeloma regimen elicited responses in 76% of 17 patients with relapsed/refractory disease.

Dr. Brudno on Allogeneic T Cells Expressing an Anti-CD19 CAR in B-Cell Malignancies

December 7th 2015

Jennifer N. Brudno, MD, medical oncology fellow, National Cancer Institute, discusses a study examining allogeneic T cells expressing an anti-CD19 chimeric antigen receptor (CAR), which was found to cause remissions of B-cell malignancies after allogeneic hematopoietic stem cell transplantation without causing graft-versus-host disease.

High Response Rates Seen With CAR T-Cell Therapies for NHL

December 7th 2015

Updated findings from early stage clinical trials exploring chimeric antigen receptor-modified T-cell therapies continue to highlight the effectiveness of these approaches for patients with non-Hodgkin lymphoma.

Adding Rituximab to Chemo Boosts Survival in Subgroup of ALL Patients

December 7th 2015

Two-year event-free survival increased from 52% with conventional therapy to 65% with the addition of rituximab among patients with newly diagnosed, CD20-positive Philadelphia (Ph)-chromosome negative B-cell precursor acute lymphoblastic leukemia, according to results from a phase III trial.

Midostaurin Shows Rare Survival Improvement in FLT3-Mutated AML

December 7th 2015

Patients with FLT3-mutated acute myeloid leukemia lived significantly longer when treated with the multikinase inhibitor midostaurin compared with placebo.

Dr. Harrison on 5-Year Follow-Up Data on Ruxolitinib in Patients With Myelofibrosis

December 6th 2015

Claire Harrison, MD, deputy clinical director of Cancer and Hematology, Guy's and St. Thomas' NHS, discusses 5-year follow-up data examining ruxolitinib in patients with myelofibrosis.

Venetoclax Sparks High Response Rate in Poor-Risk CLL Subtype

December 6th 2015

Venetoclax, demonstrated an overall response rate of nearly 80% among patients with chronic lymphocytic leukemia harboring the chromosome 17p deletion.

Frontline Ibrutinib Significantly Improves Survival in CLL

December 6th 2015

Ibrutinib reduced the risk of death by 84% versus chlorambucil in treatment-naÃ¯ve elderly patients with chronic lymphocytic leukemia.

Eltrombopag Improves Response Rates in Severe Aplastic Anemia

December 6th 2015

More than a third of patients with severe aplastic anemia achieved hematologic responses lasting at least 6 months with the addition of the oral thrombopoietin inhibitor eltrombopag to conventional immunosuppressive therapy.